Cancer Biomarkers Are Opportunity To Predict Tumor Response, Relapse Risk
Oncologic biomarkers could be used to predict tumor response or risk of relapse in certain cancer patients, FDA Deputy Commissioner for Operations Janet Woodcock said March 21
You may also be interested in...
FDA's biomarker qualification guidance will establish a "fitness for use" standard for marker validation, Deputy Commissioner for Operations Janet Woodcock said
FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16
Drug safety will remain a primary focus of FDA's guidance development efforts, according to the Center for Drug Evaluation & Research's 2006 guidance agenda